Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice 2024

San Diego, CA US

September 19, 2024 to September 21, 2024

This course offers Live (in-person) and Livestream (virtual) attendance options.

Course Directors: Benjamin Lai, M.B., B.Ch., B.A.O., Oludare, Olatoye, M.D., and Julie L. Cunningham, Pharm.D., R.PH.

September 19 - 21, 2024 - Sheraton San Diego Hotel & Marina - San Diego, California

The Mayo Clinic Opioid Conference: Evidence, Clinical Considerations & Best Practice 2024 aims to highlight the shift in guidelines and public concern regarding the use of opioids in medical practice. This course provides the most up-to-date information regarding the appropriate indication for opioids in clinical practice. Topics cover the basics of opioid pharmacology and selection, evidence-based guidelines for opioid management, opioid tapering and legal considerations, as well as medical and interventional alternatives to opioids. In addition, the course covers a broad range of issues, including opioid use disorder and difficult patient conversations and guidelines to standardize the practice of opioid prescribing. This course includes lectures by experts in the field of pain medicine and opioid management as well as question and answer sessions.

This continuing education activity satisfies the new one-time, eight-hour training requirement for all Drug Enforcement Administration (DEA)-registered practitioners. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This topic is important and has become a more visible public health issue. All fields within medicine that provide direct patient care are impacted, including medical, surgical and outpatient settings. All providers who prescribe (MD, DO, NP, PA, CNS) or administer (nurse, pharmacist, etc.) opioids to patients would benefit from attending this course. This course is particularly relevant for primary care providers that maintain and monitor patients on chronic opioid therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss current state of the opioid epidemic.
Describe the implications of CDC Opioid Prescribing Guidelines in various phases of care.
Formulate strategies on how to have conversations with patients with challenging pain conditions such as pain sensitization and unexpected urine drug testing results.
Discuss best practices on tapering opioids in clinical practice.
Review non-opioid adjuvant procedural and pharmacological therapy for pain management.
Review legal requirements regarding opioid prescribing.
Review regulatory guidelines regarding opioid prescribing.
Discuss the use of buprenorphine for pain management.
Discuss the use of buprenorphine for opioid use disorder along with its effects on transitions of care.

Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.

Course summary

Available credit:

17.00 AAFP Prescribed
16.75 AAPA Category 1 Self-assessment
16.75 ACPE
16.75 AMA PRA Category 1 Credit™
16.75 ANCC
16.75 Attendance
16.75 IPCE

Event starts:

09/19/2024 - 7:30am

Event ends:

09/21/2024 - 12:30pm

Mayo Clinic Opioid Conference:
Evidence, Clinical Considerations and Best Practice 2024
San Diego, CA
September 19-21, 2024
Pacific Time

PDF/Printable Version

Thursday, September 19, 2024

6:30 a.m.

Registration and Breakfast

Bel Aire Lobby

7:30 a.m.

Welcome and Course Overview
Dare O. Olatoye, M.D., Benjamin Lai, M.B., B.Ch., B.A.O., and Julie L. Cunningham, Pharm.D., R.Ph.

Ice breaker questions

7:40 a.m.

Current State: Guidelines, Regulations, Recommendations, and Challenges (DEA)

Benjamin Lai, M.B., B.Ch., B.A.O.

Discuss the current state of the opioid epidemic and how Covid has affected it

Summarize current legislative efforts to control opioid prescribing
Synthesize current major guidelines, requirements, and laws regarding chronic opioid prescribing
Discuss risk of Opioid Use Disorder, tolerance & central sensitization/opioid-induced hyperalgesia with chronic opioid use

8:20 a.m.

CDC Opioid Prescribing Guidelines: Application in Transitions of Care

Robert J. Hyde, M.D., M.A. & Gretchen A. Colbenson, M.D.

Describe how the guidelines differ (2016 vs 2022) and how these will affect practices for acute, subacute, and chronic prescribing

Describe transitions of care related to opioid therapy between the emergency department and inpatient setting with a case scenario
Review considerations of opioid management at hospital discharge

9:00 a.m.

Clinical Pearls for Opioid Prescribing (DEA)

Julie L. Cunningham, Pharm.D., R.Ph.

Differentiate the clinically relevant pharmacology of various commonly used opioids
Identify rational opioid treatment choices based on patient and medication factors
Discuss place in therapy for low dose naltrexone (LDN)
Describe prevalence and risks of concurrently use of opioids with sedating agents

9:40 a.m.

Refreshment Break

9:55 a.m.

Opioids in Medical Illness/Complex Pain Scenarios

Dan K. Partain, M.D.

Examine how to prevent avoidable side effects in patients with a serious illness who are being treated with opioids.
Develop a stepwise approach to the use of opioids in patients with liver & renal failure.
Discuss how to choose safe prescribing options for opioids in the treatment of non-pain symptoms.
Discuss the use of methadone for pain management

10:35 a.m.

Medical Marijuana and CBD Products: Pro Con Debate

Thomas P. Pittelkow, D.O., M.P.H.

Examine differences between medical marijuana and CBD
Review Benefits/challenges to common medical indications (e.g. cost, coverage, travel across state lines)
Describe the steps to evaluate appropriate candidacy, monitor use and evaluate for side effects and drug interactions
Summarize the evidence for/against the therapeutic benefits and risks and place in therapy as opioids alternatives or adjuvants

11:15 a.m.

Buprenorphine: Use in Pain Management and Opioid Use Disorder (DEA)

Mark E. Deyo-Svendsen, M.D.

Summarize the clinically relevant pharmacology of buprenorphine
Describe OUD screening/monitoring and when to prescribe buprenorphine
Review the available buprenorphine formulations and examine differences
Discuss challenges, potential side effects, and contraindications with buprenorphine

11:55 a.m.

Buprenorphine Patient Cases at Transitions of Care: Panel Discussion (DEA)

Dare O. Olatoye, M.D., Benjamin Lai, M.B., B.Ch., B.A.O., and Julie L. Cunningham, Pharm.D., R.Ph.

Describe transitioning full mu opioid agonist to Buprenorphine

Case: Patient with “red flags” for opioid misuse

Discuss patients where low dosing of buprenorphine would be preferred over standard initiation dosing

Case: Patient with past opioid tapering failures and high degree of distress

Review the evidence for duration of use for buprenorphine.

Case: patient stable on buprenorphine now wants to discontinue

12:35 p.m.

Adjourn

6:30 a.m.

Registration and Breakfast

7:30 a.m.

Welcome and Course Overview
Dare O. Olatoye, M.D., Benjamin Lai, M.B., B.Ch., B.A.O., and Julie L. Cunningham, Pharm.D., R.Ph.

7:40 a.m.

Current State: Guidelines, Regulations, Recommendations, and Challenges (DEA)
Benjamin Lai, M.B., B.Ch., B.A.O.

8:20 a.m.

CDC Opioid Prescribing Guidelines: Application in Transitions of Care
Robert J. Hyde, M.D., M.A. & Gretchen A. Colbenson, M.D.

9:00 a.m.

Clinical Pearls for Opioid Prescribing (DEA)
Julie L. Cunningham, Pharm.D., R.Ph.

9:40 a.m.

Refreshment Break

9:55 a.m.

Opioids in Medical Illness/Complex Pain Scenarios
Dan K. Partain, M.D.

10:35 a.m.

Medical Marijuana and CBD Products: Pro Con Debate
Thomas P. Pittelkow, D.O., M.P.H.

11:15 a.m.

Buprenorphine: Use in Pain Management and Opioid Use Disorder (DEA)
Mark E. Deyo-Svendsen, M.D.

11:55 a.m.

Buprenorphine Patient Cases at Transitions of Care: Panel Discussion (DEA)
Dare O. Olatoye, M.D., Benjamin Lai, M.B., B.Ch., B.A.O., and Julie L. Cunningham, Pharm.D., R.Ph.

12:35 p.m.

Adjourn

Thursday, September 19, 2024
Opioids & Pain Management: Interactive Case Reviews & In-Depth Discussion

(Optional $200 Add-on, Lunch Included) (DEA)

1:00 p.m.

The workshop will focus on opioids and challenging patient cases. Topics will include: tapering, managing patients on multiple controlled substances, unique scenarios across the lifespan, use of buprenorphine across clinical settings, applying 2022 CDC opioid prescribing guidelines in case-based scenarios. An opportunity for audience questions.

Benjamin Lai, M.B., B.Ch., B.A.O., Dare O. Olatoye, M.D., Julie L. Cunningham, Pharm.D., R.Ph., Andy A. Bock, D.O., Nathan T. Smith, Pharm.D., R.Ph., BCPS, Charles P. Hannon, M.D., M.B.A., Kim A. Bremseth, M.S.N., R.N.

Learning objectives below:

Review the role of opioids in acute, subacute, and chronic pain management.
Discuss the key components involved in monitoring patients on chronic opioids.
Demonstrate how to manage patients with opioid use disorder.
Integrate the 2022 CDC opioid prescribing guidelines into clinical practice across the lifespan.

4:15 p.m.

Adjourn

Friday, September 20, 2024

6:30 a.m.

Breakfast

Bel Aire Lobby

7:25 a.m.

Welcome
Dare O. Olatoye, M.D., Benjamin Lai, M.B., B.Ch., B.A.O., and Julie L. Cunningham, Pharm.D., R.Ph.

7:30 a.m.

Managing Challenges: Behaviors and Conversations

Wesley P. Gilliam, Ph.D., L.P.

Discuss case examples of difficult patient encounters
Describe the concept of central sensitization in chronic pain
Identify factors that contribute to difficult encounters with patients
Discuss practical strategies for managing difficult patient encounters

8:10 a.m.

CAREFUL Approach to Monitoring Patients on Controlled Substances & the Evidence of Combining the use of Opioids, Benzodiazepines and Other CNS Depressants

Nathan T. Smith, Pharm.D., R.Ph., BCPS & Kim A. Bremseth, M.S.N., R.N.

Describe the role of nurses in monitoring patients on chronic opioids using the CAREFUL approach
Describe the evidence that supports the risk of co-prescribing opioids and CNS depressants
Discuss the evidence for long-term use of benzodiazepines, muscle relaxants and gabapentinoids
Review benzodiazepine tapering best practices and case examples

8:50 a.m.

Interventional Alternatives for Pain Management

Tim J. Lamer, M.D.

Identify some of the most common interventional pain therapies & indications
Review an algorithm or framework for incorporating interventional pain therapies
Discuss ultrasound guided interventions in office and training
Illustrate common precautions &/or contraindications for interventional therapies including pain pump criteria, and peripheral nerve stimulators

9:30 a.m.

Harm Reduction: Naloxone/New Illicit Drugs/Fentanyl Strips (DEA)

Christopher J. Arendt, Pharm.D., R.Ph.

Discuss new formulations of naloxone and when to prescribe
Examine how to access naloxone and implication of OTC status
Describe the new worrisome illicit substances present and naloxone activity
Describe other potential harm reduction strategies such as fentanyl strips and safe supply
Discuss emerging street drugs (eg gas station heroin & xylazine)

10:10 a.m.

Refreshment Break

10:25 a.m.

Supplements Commonly Used in Chronic Pain: What is the Evidence?

Linda Huang, Pharm.D., R.Ph., BCPS

Review case base examples for considerations for supplement use in chronic pain patients
Identify literature exploring the use of select supplements associated with chronic pain
Review a patient case highlighting potential supplement use concerns

11:05 a.m.

A Surgeon’s Perspective on Pain & Opioids: Myths and Pearls (DEA)

Charles P. Hannon, M.D., M.B.A.

Discuss the approach for patient using chronic opioids with surgical needs.
Discuss a surgeon’s role in opioid stewardship
Review the pros and cons of NSAIDs use post-operatively

Describe the ideal collaboration between the primary care physician and surgeon for patient pre and post-operative pain management

11:45 a.m.

Nonopioid Adjuvants

James C. Watson, M.D.

Describe common reasons patients fail first line neuropathic pain adjuvants and practical approaches to maximize the chance of success with currently available agents
Discuss the limitations of evidence based neuropathic pharmacologic treatment algorithms

Review Clinical and Comorbidity variables that inform selection of second line non-opioid adjuvants using a patient case

12:25 p.m.

Adjourn

Saturday, September 21, 2024

6:30 a.m.

Breakfast

Bel Aire Lobby

7:25 a.m.

Welcome

Dare O. Olatoye, M.D., Benjamin Lai, M.B., B.Ch., B.A.O., and Julie L. Cunningham, Pharm.D., R.Ph.

7:30 a.m.

Urine Drug Testing and Patient Conversations (DEA)

Loralie J. Langman, Ph.D. & Benjamin Lai, M.B., B.Ch., B.A.O.

Integrate urine drug testing to support the treatment and monitoring of pain management patients.
Describe the limitations of various screening and quantitative urine drug tests.
Interpret urine drug testing results from pain management patients.
Describe techniques to start conversations for unexpected UDT results

8:10 a.m.

Using Opioids in Older Adults (DEA)

Daniel E. Sanchez Pellecer, M.D.

Develop a general framework to use opioids in older adults by
Review normal physiology changes of aging
Review polypharmacy implications when treating pain in older adults
Describe a practical approach to assess pain in cognitively impaired older adults
Review common opioid side effects in older adults
Describe how to retain pearls to the use of non-opioid pain adjuvants
Describe transitions of care pitfalls

8:50 a.m.

Opioid Side Effects and Management (DEA)

Leslie R. Siegel, Pharm.D., R.Ph.

Recognize which opioid side effects are typically transient and which are pervasive.

Discuss management options for each opioid side effect discussed (remove testosterone)
Compare when to rotate opioid vs. when to treat the symptom.
Identify the risk for depression with opioid use, how to evaluate and treatment strategies

9:30 a.m.

Biopsychosocial Spiritual Model of Chronic Pain & OUD
Holly L. Geyer, M.D. & Robert W. Kirchoff, M.D., M.S.

Discuss Case-based patient: how to manage the biological, psychological, social & spiritual aspects of patients with chronic pain & OUD using a case-based approach.
Describe how to assess each of these aspects; what resources might need to be considered to address needs?
Discuss provider burnout with the management of chronic pain patients & OUD patients: how providers would also benefit from a biopsychosocial-spiritual approach (to potentially reduce burnout) Resources for patients to manage the biological, psychological, social and spiritual needs of patients to optimize management of chronic pain & OUD

10:10 a.m.

Refreshment Break

10:25 a.m.

Acute Pain Management for the Patient on Chronic Opioids (DEA)

Dare O. Olatoye, M.D.

Discuss the clinical burden of patients on chronic opioid Therapy

Describe medication options used by patients on chronic opioid Therapy
Discuss implications of patients on MOUD
Review acute pain management strategies of patients on Chronic Opioid Therapy

11:05 a.m.

Tapering Opioids (DEA)

Julie L. Cunningham, Pharm.D., R.Ph.

Review and discuss the evidence-based literature and guidelines regarding opioid tapering
Describe the primary risks associated with opioid tapering
Discuss opioid tapering tips, tricks, barriers, and pitfalls
Describe best practices for communicating with patients before and during opioid tapering
Discuss full mu opioid to buprenorphine taper example

11:45 a.m.

Legal Implications of Opioid Prescribing (DEA) (virtual)

Erin C. Skold, J.D.

Discuss overview of potential legal implications of opioid prescribing in a case-based scenario

Review special considerations for chronic pain prescribing
Review special considerations for hospice and palliative care patients
Describe current state of telemedicine prescribing for opioids
Review overview opioid prescribing and provider responsibility to document and prescribe risk mitigation strategies

12:25 p.m.

Closing Remarks

12:30 p.m.

Adjourn

Sheraton San Diego Hotel & Marina

95936 street

Apt 24

San Diego, CA 39242

United States

Sheraton San Diego Marina - 1380 Harbor Island Drive, San Diego, CA 92101

Guest rooms have been reserved for attendees and their guests with special course rates at the Sheraton San Diego Marina. The group rate at the hotel is $269.00. In order to receive the special rates, reservations must be made before the room block is filled or before the expiration date of September 3, 2024, whichever comes first. After September 3, 2024, reservations will be taken based on space and rate availability. Each attendee is allowed one guest room at the special course room rate.

BOOK NOW
Bay Town Run of House - $269.00

Resort Experience Fee
Please note that there is an additional charge of $20.00 per room per night plus tax that is not included in the above room rates. The following amenities are bundled into this charge:

Fitness & Recreation

Premium high-speed internet access
Morning Yoga class
1-hour cruiser bicycle use
1.5-hour paddle board tour & lesson
1-hour daily tennis court rental with equipment for two
Lawn games
S’mores
Unlimited local & domestic long-distance phone calls
Electric vehicle charging

Transportation

Complimentary Airport shuttle transportation to and from the San Diego International Airport.

All travel and lodging expenses are the sole responsibility of the individual registrant.

Course Directors:

Benjamin Lai, M.B., B.Ch., B.A.O.

Oludare, Olatoye, M.D.

Julie L. Cunningham, Pharm.D., R.PH.

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s):

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA
Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 16.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

AAFP
The AAFP has reviewed Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice 2024 and deemed it acceptable for up to 17.00 Live AAFP Prescribed credit(s). Term of Approval is from 09/19/2024 to 09/21/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

ACPE
Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 16.75 ACPE Knowledge contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity.

UAN Number: JA0000238-0000-24-114-L08-P

ANCC
Mayo Clinic College of Medicine and Science designates this activity for a maximum of 16.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

IPCE
This activity was planned by and for the healthcare team, and learners will receive 16.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Other Healthcare Professionals:
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.

Day - Session	Credit
Thursday - General Session	4.75
Thursday - Workshop	3.00
Friday - General Session	4.50
Saturday - General Session	4.50

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

Available Credit

17.00 AAFP Prescribed
16.75 AAPA Category 1 Self-assessment
16.75 ACPE
16.75 AMA PRA Category 1 Credit™
16.75 ANCC
16.75 Attendance
16.75 IPCE

In response to company inquiries, we are excited to share that the Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice 2024 has expanded its commercial support offerings to include a variety of sponsorship opportunities! Please check out our comprehensive prospectus.

If you are interested in exhibiting, please complete the Letter of Agreement.

If you are interested in Sponsoring, please contact Lisa Winter

If you have additional questions, please contact: Lisa Winter

Status

Price

Title

Locked

$0.00Included

Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice 2024